Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy

Autor: Park, H, Garrido-Laguna, I, Naing, A, Fu, S, Falchook, GS, Piha-Paul, SA, Wheler, JJ, Hong, DS, Tsimberidou, AM, Subbiah, V, Zinner, RG, Kaseb, AO, Patel, S, Fanale, MA, Velez-Bravo, VM, Meric-Bernstam, F, Kurzrock, R, Janku, F

Publikováno v: Oncotarget, vol 7, iss 41
Park, H; Garrido-Laguna, I; Naing, A; Fu, S; Falchook, GS; Piha-Paul, SA; et al.(2016). Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. ONCOTARGET, 7(41), 67521-67531. doi: 10.18632/oncotarget.11750. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/1dp7g79p

Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::512319f3ff14299dfb14919f0d8072de
https://escholarship.org/uc/item/1dp7g79p

Co-occurring mutations identify prognostic subgroups of microsatellite stable colorectal cancer.

Autor: Nunes, Luís¹ (AUTHOR) luis.nunes@ous-research.no, Stenersen, Jakob Mørkved^1,2 (AUTHOR), Kryeziu, Kushtrim¹ (AUTHOR), Sjöblom, Tobias³ (AUTHOR), Glimelius, Bengt³ (AUTHOR), Lothe, Ragnhild A.^1,2 (AUTHOR), Sveen, Anita^1,2 (AUTHOR)

Publikováno v: Molecular Cancer. 11/25/2024, Vol. 23 Issue 1, p1-7. 7p.

Defining the transcriptome of PIK3CA-altered cells in a human capillary malformation using single cell long-read sequencing.

Autor: Wedemeyer, Michelle A.^1,2,3,4 (AUTHOR), Ding, Tianli¹ (AUTHOR), Garfinkle, Elizabeth A. R.¹ (AUTHOR), Westfall, Jesse J.¹ (AUTHOR), Navarro, Jaye B.¹ (AUTHOR), Hernandez Gonzalez, Maria Elena¹ (AUTHOR), Varga, Elizabeth A.¹ (AUTHOR), Witman, Patricia^2,5 (AUTHOR), Mardis, Elaine R.^1,2,4 (AUTHOR), Cottrell, Catherine E.^1,2,6 (AUTHOR), Miller, Anthony R.¹ (AUTHOR), Miller, Katherine E.^1,2 (AUTHOR) Katherine.Miller@nationwidechildrens.org

Publikováno v: Scientific Reports. 10/25/2024, Vol. 14 Issue 1, p1-10. 10p.

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.

Autor: Janku F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. fjanku@mdanderson.org., Park H; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Internal Medicine (Division of Oncology), Washington University School of Medicine, St. Louis, Missouri., Call SG; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Madwani K; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Oki Y; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Subbiah V; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hong DS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Naing A; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Velez-Bravo VM; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Barnes TG; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hagemeister FB; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Falchook GS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Karp DD; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wheler JJ; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Piha-Paul SA; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Garrido-Laguna I; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shpall EJ; Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fayad LE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Neelapu SS; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Meric-Bernstam F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kurzrock R; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fanale MA; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Nov 01; Vol. 26 (21), pp. 5579-5587. Date of Electronic Publication: 2020 Oct 14.

How to Build a Successful Phase I Clinical Trials Unit: Lessons Based on the MD Anderson Cancer Center Experience.

Autor: Kurzrock, Razelle^1,2,3 rkurzrock@mcw.edu, Hong, David⁴

Publikováno v: Journal of Immunotherapy & Precision Oncology. Aug2024, Vol. 7 Issue 3, p142-149. 8p.